secretagogue


Also found in: Medical, Wikipedia.

se·cre·ta·gogue

 (sĭ-krē′tə-gôg′, -gŏg′)
n.
A hormone or another agent that causes or stimulates secretion.

secretagogue

(sɪˈkriːtəɡɒɡ)
n
(Medicine) med a substance that stimulates secretion
seˌcretaˈgogic adj
Translations

se·cre·ta·gogue

, secretogogue
n. secretogogo, agente que estimula la secreción glandular.
References in periodicals archive ?
Ardelyx is also developing RDX013 -- a small molecule secretagogue -- for the treatment of hyperkalemia.
On the basis of products, the dry eye disease market is categorized into artificial tears, anti-inflammatory drugs, punctal plugs, secretagogue and others.
GHRL is the endogenous ligand of growth hormone secretagogue (GHSR) discovered by (Kojima et al., 1999).
* Drug class, e.g., sensitizer vs secretagogue, incretin drugs, insulin therapy
Caprio described the two-step hyperglycemic clamp as "a robust approach to quantification of insulin sensitivity and beta-cell responses to both glucose and the nonglucose secretagogue arginine.
The actions of GHRL are mediated by binding to the growth hormone secretagogue receptor (GHS-R) which is a G-protein-coupled receptor.
"It verifies that Renuva is an effective HGH precursor and secretagogue. We're not aware of any other company that has actually subjected their anti-aging supplement formulation to this kind of clinical trial, or achieved these kinds of results and have their study published," he said.
The growth hormone secretagogue receptor (GHS-R) mediates the different actions of the synthetic growth hormone secretagogues (GHS) and the endogenous ligand of this receptor, ghrelin (6).
Macrilen is a prescription oral test that has been granted orphan drug designation in the United States, as the first and only FDA-approved oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency, a rare endocrine disorder.
The guideline also makes no recommendation on the use of the intestinal secretagogue lubiprostone or the 5HT agonist prucalopride.
Macimorelin (Macrilen) (MW 535) is an oral growth hormone secretagogue receptor agonist.
On December 20, 2017, the US Food and Drug Administration granted marketing approval for Macrilen, an oral growth hormone secretagogue receptor agonist, to be used in the diagnosis of patients with adult growth hormone deficiency.
Full browser ?